Using a new imaging technique to target a specific protein in aggressive prostate cancer
Targeting CD133 for imaging and therapy in prostate cancer
This study is working on new ways to see and treat aggressive variant prostate cancer by creating special imaging tools and therapies that target a specific protein on cancer cells, aiming to help patients who have this tough-to-treat condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10653106 on NIH RePORTER |
What this research studies
This research focuses on developing advanced imaging techniques and therapies for aggressive variant prostate cancer (AVPC), a type of cancer that does not respond to standard treatments. The team aims to create positron emission tomography (PET) imaging probes and radioimmunotherapy agents that specifically target a unique protein called CD133 found on cancer cells. By utilizing innovative antibody constructs, they hope to improve the accuracy of imaging and treatment for patients with AVPC, which is crucial for managing this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with aggressive variant prostate cancer who have not responded to conventional therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone second-generation anti-androgen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective imaging and treatment options for patients with aggressive prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting specific cancer markers for imaging and therapy, suggesting that this approach could be effective.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Lebeau, Aaron Matthew — University of Wisconsin-Madison
- Study coordinator: Lebeau, Aaron Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.